•  
  •  
 

Abstract

To date, SARS-CoV-2 has infected more than 32 million people, and 30% of cases needs intensive care treatment for severe Covid-19 and related acute respiratory distress syndrome (ARDS). Despite medical efforts, mortality rate is still high, and no specific therapies have been outlined yet. Preliminary evidence from case reports and clinical trials using anti-inflammatory and anti-complement drugs shows a deep and overwhelmed inter-play between adaptive and immune responses triggered by SARS-CoV-2 infection. Therefore, a combinatorial therapeutic strategy targeting both inflammation and immune system might more efficiently stop this inflammatory loop and prevent the development of ARDS.

Share

COinS